News Releases

Advanced Search
  • Oct 16, 2019
    GtreeBNT Meets with Multinational Pharma Companies at AAO in Anticipation of Completion of Phase 3 Clinical Trial

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, released a summary...

  • Sep 30, 2019
    Enrollment on Target for Completion of Phase 3 Dry Eye Trial in Q2 2020

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that...

  • Sep 10, 2019

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...

  • Sep 4, 2019

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...

  • Aug 5, 2019
    RegeneRx Licensee Sponsoring the Phase 2 U.S. Clinical Trial

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today confirmed that...

Show 5102550100 per page